DEC 0 8 2003 P

hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450,

on <u>Decembry</u>, 200 Edate of Deposit)

1 4 4 0 3

Name

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Attorney Docket No. 01-1736-D)

In re Application of:
 Hom et al.
 Before the Examiner:
 T. Criares

Serial No.: 09/816,876

Art Unit: 1617

Filed: March 23, 2001

For: Compounds to Treat
 Alzheimer's Disease

Alzheimer's Disease

Defore the Examiner:
 T. Criares

Confirmation No.: 6062

RESPONSE TO THE RESTRICTION REQUIREMENT MAILED SEPTEMBER 4, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Restriction Requirement mailed September 4, 2003, Applicants elect the claims of Group V, i.e., claims 49-59, for prosecution. Further, Applicants elect the species of Example 53 on page 174. The compound of that example is named in the specification as 4-(anti)-([6-(3,5-Difluorophenyl)-5-(S)-(3-dipropylcarbamoyl-benzoylamino)-4-(S)-hydroxyl-

2-(R)-isobutyl-hexanoylamino]-methyl)-cyclohexanecarboxylic acid: and can be represented by the following structure:

Applicants urge the Examiner to contact the Applicants' undersigned representative at (312) 913-0001 if it is believed that a discussion would expedite prosecution of this application.

Respectfully submitted,

Dated: December 4, 2003 By:

Steven J. Sarussi Reg. No. 32,784

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive Chicago, Illinois 60606 (312) 913-0001